Muhammad Sethi
Endocrinology, Diabetes & Metabolism · Tucson, AZNPI 1275762130
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $544,021 of the $669,855 with a category attached, or 81.2%. 26 manufacturers reported payments, led by Novo Nordisk at 34.7% of the total. Reporting peaked in 2019 at $389,202 and has fallen 94.0% since, to $23,159 in 2025. Among endocrinology, diabetes & metabolism clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 973 payments — averaging $688.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$233K
- Amgen$179K
- Lilly USA, LLC$134K
- Shire North American Group Inc$68K
- Boehringer Ingelheim$22K
- Amarin Pharma, Inc.$22K
- plus $12K from 20 others
What the payments were for
- Consulting fees$12,2482%
- Speaking & faculty fees$544,02181%
- Travel & lodging$96,76914%
- Food & beverage$16,6642%
- Education$1540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 245 | $232,766 |
| Amgen(2 entities) | 222 | $178,530 |
| Lilly USA, LLC | 234 | $133,991 |
| Shire North American Group Inc | 116 | $67,574 |
| Boehringer Ingelheim | 26 | $22,380 |
| Amarin Pharma, Inc. | 36 | $22,181 |
| Johnson & Johnson | 10 | $7,886 |
| Sanofi-aventis U.S. LLC | 30 | $3,567 |
| Sequel Med Tech, LLC | 2 | $184 |
| Dexcom, Inc. | 11 | $155 |
| AbbVie | 8 | $126 |
| Mannkind Corporation | 7 | $96 |
| Abbott | 3 | $70 |
| Nestle Healthcare Nutrition Inc. | 2 | $47 |
| Medtronic | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Novartis | 2 | $36 |
| Antares Pharma, Inc. | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Merck | 2 | $24 |
| Radius Health, Inc. | 1 | $18 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Travere Therapeutics, Inc. | 3 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$102,529
- RYBELSUS$95,593
- Prolia$89,997
- Ozempic$81,432
- NATPARA (PARATHYROID HORMONE)$65,872
- EVENITY$56,747
- JARDIANCE$33,116
- Repatha$29,298
- Vascepa$21,531
- Tresiba$16,726
- INVOKANA$7,752
- Xultophy 100/3.6$6,788
- DISEASE STATE$3,048
- TWIIST$105
How this compares
$669,855 in reported general payments places this provider in the 95th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 476 | $872,212 |
| TrulicityDulaglutide | 215 | $362,082 |
| KorlymMifepristone | 13 | $262,210 |
| VascepaIcosapent Ethyl | 249 | $215,191 |
| FarxigaDapagliflozin Propanediol | 168 | $210,662 |
| JardianceEmpagliflozin | 135 | $197,540 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 174 | $132,270 |
| Tresiba Flextouch U-200Insulin Degludec | 102 | $127,794 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $125,267 |
| ForteoTeriparatide | 25 | $113,985 |
| MounjaroTirzepatide | 55 | $78,455 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 41 | $78,211 |
| Tresiba Flextouch U-100Insulin Degludec | 102 | $77,959 |
| RybelsusSemaglutide | 35 | $75,233 |
| Humalog Kwikpen U-100Insulin Lispro | 144 | $56,029 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $232,766 | $978,668565 claims |
| Lilly USA, LLCTrulicity, Forteo, Mounjaro, Humalog, Insulin Lispro | $133,991 | $576,976394 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $22,380 | $209,478149 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $3,567 | $90,923102 claims |
| AbbVieSynthroid | $126 | $21,024167 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $9,641957 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Tucson
- Karen HerbstTucson$200K
- Nora BarsonyTucson$121K
- Maria PosadasTucson$24K
- Dorota PucykTucson$15K
- Neda EbrahimiTucson$11K
- Casey RendonTucson$9K
- Jonathan InselTucson$7K
- Roshanak HabibiTucson$7K
- Ramiro Cardenas LaraTucson$6K
- Cynthia Rivas PajueloTucson$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.